Mutations of NPM1 or FLT3-ITD are the most prevalent mutations within the group of normal karyotype AML, where mutated NPM1 comprises approximately 40–50% of cases and FLT3-ITD approximately 30–40%.12 During the course of the phase III trial, analyses of NPM1 and FLT3-ITD were not part of clinical practice. Here, NPM1 is linked to acute myeloid leukemia.